IL6 and neoplasm: In a follow-up study, Yang et al. [2021] showed that the combination of IL-6 inhibition with a T cell activator, a CD40 agonist, reversed macrophage-mediated tumor suppression, sensitized the tumors to immune checkpoint blockade (ICB), and extended survival in two syngeneic GBM models, while completely eradicating GL261 tumors [Yang et al., 2021].